Seminars in Hematology
Volume 47, Issue 2 , Pages 107-114, April 2010

CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies

Tenovus Laboratory, Cancer Sciences Division, University of Southampton School of Medicine, General Hospital, Southampton, UK

The last decade has seen the monoclonal antibody (mAb), rituximab, transform clinical management of many non-Hodgkin lymphomas and more recently provide new opportunities for controlling autoimmune conditions, such as rheumatoid arthritis. Although not yet fully determined, the explanation for this success appears to lie with the inherent properties of its target, CD20, which allow rituximab to recruit potent cytotoxic effectors with unusual efficiency. In this review we detail the properties of CD20 that make it such an effective therapeutic target and describe how different mAbs change the membrane distribution and internalization of CD20 and have distinct modes of cytotoxic activity.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by Leukaemia Research, Cancer Research UK, Association for International Cancer Research, and the Medical Research Council.

PII: S0037-1963(10)00002-8

doi:10.1053/j.seminhematol.2010.01.001

Seminars in Hematology
Volume 47, Issue 2 , Pages 107-114, April 2010

Article Tools

* Image Usage & Resolution